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In the context of cancer therapy and personalized 
medicine, a growing interest is now being paid 
toward theranostic agents, i.e. materials bearing at 
the same time diagnostics and therapy functions1. 
For this purpose, nanoparticles (NPs) are being 
investigated, because of their potential of being 
engineered with precise sizes, shapes, composition, 
and with surface-targeting ligands that allow a 
specific interaction with target cells2,3. The 
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combination in the same NP of light-based 
diagnostics and therapy functions have become 
indispensable tools to address patient-specific 
characteristics of cancer, claiming an increasing 
interest in applied research for personalized 
medicine4,5. 
In the case of cancer, NPs preferentially accumulate 
in tumors due to the enhanced permeability and 
retention effect6. In fact, nanosystems with long 
circulation times accumulate preferentially into 
tumor tissue through a leaky tumor vasculature and 
are retained in the tumor bed due to reduced 
lymphatic drainage. This process is known as the 
enhanced permeability and retention (EPR) effect. 
Most nano-sized systems accumulate within tumors 
due to the EPR effect7 and thus in principle they can 
improve the performance of radionuclide therapy8. 
The utilization of NPs has a particular advantage, as 
they are able to achieve a large dispersion within 
tumor the tissue and closely interact with specific 
sub cellular structures9. In order to be efficiently 
employed in radionuclide therapy, NPs are required, 
i) to be rapidly synthetized, ii) rapidly reach their 
target (tumor cells) and mainly accumulate near or 
inside it, iii) release sufficient energy to destroy 
tumor cells, iv) to be easily eliminated body without 
secondary damage10,11.  
89Sr and 131I are both βemitters, already employed 
in radionuclide therapy because of their low 
chemical toxicity and low half-life that reduces 
post-treatment risks. 89Sr is currently used for 
treatment of metastases and pain in bone cancer12,13, 
because of its ability to substitute the calcium ion in 
bones and thus acting selectively in these organs. 
131I-therapy is a standard ablative therapy for both 
non-malignant thyroid diseases as well as thyroid 
cancer, due to its ability to concentrate in this 
organ8. However, though a certain degree of 
selectivity to the target organ is achieved, both 
tumor and healthy cells are involved in the 
irradiation, implicating a not desirable amount of 
secondary damage to the patient. Thus, it can be 
useful to encase the radioisotopes into NPs, whose 
surface can be functionalized in order to drive them 
exclusively toward tumor cells. At the same time, 
the concentration of radioisotopes into as small 
particles can in principle enhance the efficacy of 
radionuclide therapy. 
The aim of this work is to synthetize non-toxic and 
low-cost Sr/I-based NPs with suitable modified 
surface for biological employment, in order to 
develop a new 89Sr- and/or 131I-based radionuclide 
therapy method. 
In our previous works14-16, we reported on Metal 
Organic Frameworks (MOFs) obtained by 
combining fructose with several binary salts MX2 
(M = Ca, Sr; X = Cl, Br, I), that can be utilized as 
nonlinear optics (NLO) bio-sensors. Among these 
compounds, we focused our attention to those 
containing Sr and I, since they can be usefully 
employed as carriers for 89Sr and 131I.They are 
SrCl2- and SrI2-fructose based crystalline 
compounds, of formula [Sr(C6H12O6)2 (H2O)2] 
Cl2∙H2O (1) and [Sr(C6H12O6)2]I2 (2), respectively. 
The great advantage of these systems is their 
biocompatibility, being composed of a sugar and 
several ions that are known to be metabolized by 
biological cells. In our previous works, we 
completely characterized these materials with single 
crystal X-ray diffraction (Figure No.1) and we 
discussed their NLO properties for applications as 
bio-sensor. The purpose of this work is to produce 
particles of these compounds at nano-scale 
dimensions for biological applications and to 
modify their surfacein order to allow their survival 
in a biological environment. In order to investigate 
the possible occurrence of structural and functional 
alterations related to the permanence on NPs in the 
intracellular milieu, preliminary viability and cell 
uptake assays were performed on a non-tumor cell 
line, hTET-HME1, and a tumor cell line, HT-29. 
Furthermore, the dose absorbed by cancer tissues 
exposed to 89Sr and 131I enriched NPs was 
estimated, in the perspective of evaluating the 
suitable concentration of enriched NPs to administer 
to the patient. The results are discussed in the 
context of developing novel biocompatible 
materials that can be suitably used as carriers of 
radioisotopes at the sub-cellular level. 
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MATERIAL AND METHODS 
β-D (-) fructose, SrCl2·6H2O, SrI2·6H2O, ethanol, 
exane and dodecanoyl chloride ≥ 99% were 
purchased from Sigma-Aldrich. 1, 2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-2000] (mPEG-DSPE) was 
purchased by Creative PEG Works. All reagents 
were used as supplied. 
Cells. hTERT-HME1 and HT-29 were purchased 
from American Type Culture Collection (Manassas, 
VA). hTERT-HME1 were cultured in DMEM-F12 
medium, supplemented with 2% fetal bovine serum 
(FBS), 20ng/mL Epidermal Growth Factor (EGF), 
10µg/mL insulin and 100µg/mL hydrocortisone. 
HT-29 were cultured in RPMI medium 
supplemented with 10% FBS. All cell culture media 
were supplemented with 100 units/mL penicillin, 
0.1mg/mL streptomycin, 0.25µg/mL amphotericin 
B and 2mM glutamine. 
Synthesis of Sr(C6H12O6)2 (H2O)2] Cl2∙H2O (1) 
and Sr(C6H12O6)2]I2 (2) 
Strontium salts and fructose were dissolved in 
ethanol at 338 K in the stoichiometric ratio 1:2. 
After a few minutes the reagents completely 
dissolved and a faint precipitate was deposited at 
the bottom of the solution. The precipitate was 
decanted, washed three times with ethanol, and 
dried out in an oven at 333 K. 
Synthesis of nanoparticles (NPs) 
The precipitates were ground in a planetary ball mill 
(Retsch PM 100) equipped with steel jars with 
volume of 50mL and balls with diameter of 2mm. 
The grinding parameters were: i) 200 rpm, 2 minute 
pause for each 5 minutes of grinding and ii) 
300rpm, 2 minutes pause for each 8 minutes of 
grinding. 20mg of ground powder were mixed with 
0.3mg of fluorescein and suspended through 
sonication in 2mL of hexane. The suspension was 
transferred into an agate mortar and ground with 
10µL of dodecanoyl chloride. The suspension was 
dried in an oven at 333 K. To enclose NPs in a lipid 
shell, 6 mg of the previous product were mixed with 
0.6 mg of mPEG-DSPE and 2mL of hexane. After 
30 minutes of sonication the suspension was 
quickly dried in the oven at 333K. Prior to the 
biological tests the powder obtained was suspended 
in water and sonicated for30 minutes. 
NPs characterization 
X-ray powder diffraction. XRPD patterns were 
collected at room temperature using an Oxford 
Diffraction Gemini R Ultra diffractometer. Data 
were collected with mirror monochromatized Cu-
Kα radiation (λ=1.5418 Å): maximum resolution 
1.4 Å, exposure time 30 s and data collection and 
integration with Crys Alis Pro software17. 
Size measurement. The NP average diameters and 
polydispersity index (PDI) were characterized by 
Laser Light Scattering technique (LLS), performed 
using a 90Plus Nanoparticle Size Analyzer 
equipped with a Peltier temperature control system 
(Brookhaven Instruments Corp., Holtsville, NY). 
The particle size measurements and distribution 
were carried out at 25°C, at a fixed 90° angle and a 
wavelength of 675nm. 
To maximize the accuracy of the measurement, the 
modified NPs were diluted before the LLS analysis 
by using 4mL of Milli Q water and sonicated for 30 
minutes. As a measure of an acceptable sample 
concentration, we followed the recommendation of 
the LLS equipment manufacturer that the signal 
intensity measured by the instrument lie between 
100 and 250 kilo counts per second (kcps). 
Cells and viability assay 
Viability assay. Cells were seeded in complete 
medium (100µL) at an appropriate density (1000-
10000 cells/well), in 96-well plastic culture plates in 
triplicate. The following day, after serial dilutions in 
medium, 100µL of modified NP, fructose or 
strontium chloride, in serum-free medium, were 
added to the cells using a multichannel pipette; 
medium-only containing wells were used as 
controls. Plates were incubated at 37 C in 5% CO2 
for different times (1, 2 or 5 days), after which the 
cell viability was assessed using ATP content and 
the Cell Titer-Glo® Luminescent Cell Viability 
Assay (Promega, Italia Srl, Milano, Italy). All 
luminescence measurements (indicated as relative 
light units), were recorded on a Victor X4 
multimode plate reader (Perkin-Elmer, Waltham, 
MA, USA). 
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Cell uptake. 150.000 cells were seeded in complete 
medium (250µL) in each well of a 24-well plastic 
culture plates, in triplicate. The cells were incubated 
for 24 h and subsequently treated with different 
concentrations of NPs loaded with fluorescein for 3 
or 24 h; medium-only containing wells were used as 
controls. Supernatants were collected and cells were 
washed twice with phosphate buffer saline and 
lysed using Alpha Sure Fire Ultra Lysis Buffer (5X) 
(Perkin Elmer). Both the supernatant and the 
intracellular fluorescence were recorded using an 
Ensight multimode plate reader (Perkin-Elmer, 
Waltham, MA, USA)18. 
 
RESULTS AND DISCUSSION 
Compounds 1 and 2 were rapidly synthetized using 
the direct reaction of salts and fructose in ethanol, 
that led to the formation of a faint white precipitate. 
The main disadvantage for biological application of 
this kind of materials is their high solubility in 
water. To avoid their dissolution, the NPs were 
reacted with dodecanoyl chloride, to saturate the -
OH groups on the surface and reduce their polarity. 
Ester bonds are formed on the surface of the NPs, 
and the long hydrophobic chains make the NPs 
completely waterproof, as evidenced in Figure 
No.2, where a drop of water mixed with the 
modified powder was observed on an optical stereo-
microscope (drop on the left). 
However, for biological applications the NPs should 
be able to diffuse in a water medium. For this 
purpose, we created a hydrophilic shell of mPEG-
DSPE that increases their biocompatibility. The 
NPs enveloped with mPEG-DSPE become 
completely hydrophilic, as shown by their diffusion 
into the drop of water shown on the right side of 
Figure No.2. The complete process of chemical 
modification of NPs surface is schematized in 
Figure No.3. 
In Figure No.4 reports the XRPD patterns collected 
for compounds 1 (ground for 90 min at 200rmp) 
and 2 (ground for 90 min at 300rmp), after reaction 
with dodecanoyl chloride and the subsequent 
covering with mPEG-DSPE: the comparison of the 
experimental XRPD patterns to the calculated from 
the single crystal X-ray structures of the two 
compounds shows that the crystalline core 
maintained its integrity. Thus, the intact crystalline 
frameworks of the compounds preserve their NLO 
property, that can be exploited for the bio-sensing 
of NPs inside the cells. 
To obtain NPs of suitable dimensions for biological 
applications, each dried precipitate was ground on a 
planetary ball mill, exploiting its high fragility. The 
products are stable in a wide range of temperatures, 
up to 323 K. Since they quickly degrade under an 
electron beam, it was not possible to characterize 
the primary particle sizes of NPs with SEM or TEM 
microscopes. Thus, the LLS technique was used to 
determine the particle size distribution in the sub-
micrometric range. Table No.1 reports the mean 
diameter and standard error of the particles 
modified with dodecanoyl chloride and covered 
with mPEG-DSPE, obtained with different grinding 
parameters. 
As shown in Table No.1, for both compounds the 
mean modified NPs size decreases with grinding 
time; moreover, compound 2 needs enhanced 
grinding energy with respect to compound 1 to 
obtain the same dimension. 
In conclusion, by conveniently selecting the 
grinding parameters, we can regulate the dimension 
of NPs to the biological and therapy requirements. 
Evaluation of the dose absorbed by a tissue 
exposed to enriched nanoparticles of compound1 
(89Sr(fructose)2 Cl2·H2O) and compound 2 (89Sr 
(fructose)2I2 and Sr (fructose)2131I2) 
The compounds presented in this paper, once 
enriched in89Sr or 131I, could be of interest for 
applications in biomedicine and in radiotherapy. 
Radioactive nuclides of both the cation and the 
anion can be obtained by nuclear fission, and the 
two inorganic compounds strontium chloride and 
sodium iodide are currently available in forms 
suitable for applications in radiotherapy. 89Sr, is aβ 
emitter with a half-life of 50.57 d used in the form 
of chloride for metastasized bone cancer; 131I is also 
aβ emitter with a half-life of 8.0252 d, used in the 
form of sodium iodide for hyperthyroidism and 
carcinoma of the thyroid. Considering that 
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strontium chloride and sodium iodide do not exhibit 
any selectivity towards tumor cells while 
nanoparticles can be functionalized to selectively 
bind to tumor cells, we have computed the dose 
absorbed by a tissue exposed to nanoparticles of 
89Sr(fructose)2I2 and Sr(fructose)2131I2 containing a 
number density  of the relevant radionuclide, 
assuming the radius of particles to be . 
The average energy of the β−radiation emitted 
by89Sr and 131I is 0.58 MeV ( ) 
and 0.19 MeV ( ), respectively. 
Based on the ranges computed in the continuous 
slowing down approximation of 2.3 mm (for89Sr) 
and 0.45mm (for131I), we can safely assume that the 
tumor size is about one order of magnitude larger. 
That leads to the assumption that in the tissue the 
distance between particles, each of volume , is 
smaller than the average range of the β radiation, 
and all theβ energy would be absorbed by the tumor 
tissue. Consequently, to deliver a predetermined 
dose to a tumor mass that contains within itself a 
number density of particles  and it is made of cells 
of volume , we need the specific value of the 
atomic number density  (atoms m-3) of the 
radionuclide (89Sr or131I) in the tissue, given by 
 
 
The required density  would be attained by either 
scaling the radionuclide atomic density in the 
particle ( ) or the number of particles in the cell 
( ). For example, the commercial water 
solution of89SrCl2 contains, on average, 16.75 mg of 
strontium chloride per mL with the activity of 
37MBq mL-1, corresponding to the average specific 
activity 4.565 MBq mg-1. Particles 
of89Sr(fructose)2I2 synthesized from this 
commercial solution would have a fixed atomic 
density of89Sr, and the number density 1.49 × 1022 
89Sr atoms per cubic meter can be calculated from 
the relation  (  represents the activity and  
is the 89Sr decay constant) and the 89Sr(fructose)2I2 
mass density of 2.307 × 103 kg m-3. With this value 
we evaluate  and the energy per unit mass 
absorbed by the tissue 
 
The integrated dose thus is 
 
To deliver a predetermined dose Dmin to the tumor 
mass, we would need to scale either the value of 
 or  to satisfy the equalityD = Dmin. 
In the case of 89Sr(fructose)2I2, we would need 
 for Dmin= 1 Gy (Gy = Jkg-1). Thus a 
tumor with cell radius , as in 
glioblastoma cell lines19, treated with these particles 
would be delivered a dose of 1 Gy by a particle 
density , i.e. about 1 particle in four 
cells. If the resulting distribution of particles had a 
lower density, the only way to reach the limit value 
of 1 Gy would be to resort to a starting material 
with a higher specific activity. 
On the other hand, since commercial Na131I is 
isotopic ally pure, particles of Sr(fructose)2131I2 
derived by the commercial salt would afford the 
high atomic density of131I ρ= 3.95 × 1027 m-3. To 
deliver 1 Gy, we would thus need to scale downρ 
by a factor 2.85 × 10-6 for the particle density in the 
case , i.e. only one particle per cell. 
Table No.5 reports the calculated values of  and  
for Dmin = 1Gy and Sr(fructose)2I2 labeled with 89Sr 
or 131I from 89SrCl2 or Na131I as starting reagents, 
respectively. 
In order to be able to calculate the required initial 
activity for each specific therapy, we need the initial 
activity per unit of irradiated tissue volume, as 
given by 
 
Values of  (Bq m-3) are also reported in Table 
No.2 for the compounds studied. For a tumor with 
radius 1 cm ( ) and the fraction = 
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7.57 × 10-6of radionuclide 89Sr in the starting 
compound,  = 7.16 × 103Bq, the corresponding 
amount of crystal (89Sr(fructose)2I2 or 
89Sr(fructose)2Cl2 ·  3H2O) is 
 
(Corresponding to 6.94µg and 5.67µg, 
respectively). 
The twoβ− emitters have thus complementary 
features; 89Sr exhibits a long half-life that would 
ease both the formation and the functionalization of 
the particles at the expense of a dose somehow 
limited by the factor . 
On the other hand, 131I makes a virtually unlimited 
dose readily available (in fact, it would have to be 
diluted to deliver a dose of 1 Gy with 
Sr(fructose)2131I2 particles), but it has a relatively 
short half life that calls for a fast preparation and 
use of the particles. From the above considerations, 
it should be possible to tune the therapeutic 
properties of nanoparticles by calibration of the 
amount of 89Sr and/or 131I, thus allowing the 
custom-tailoring of the therapy to the patient. 
In conclusion, equations (1) trough (5) can allow 
the custom-tailoring of the therapy to the patient 
through the estimate of the amount of enriched NPs 
to be administered to the patient once the bio-
distribution, clearance, and specific uptake are 
known. 
Viability assay 
To evaluate the effect of the NPs on cell viability, 
we treated hTERT-HME1 and HT-29 cell lines with 
five different modified NPs concentrations, in the 
range 0.25 – 0.000025mg/mL, for 1, 2 and 5 days. 
Subsequently, the cell viability was determined 
using the luminescent detection of cellular ATP 
content; each point was performed in triplicate and 
at least three times. As shown in Figure No.5, 
modified NPs of both compounds1 and 2 were not 
able to significantly influence cell viability of both 
cell lines at day 1 and 2. After 5 days the hTERT-
HME1 cell line showed sensitivity to compound 1 
at the lowest concentration, even though with a high 
standard deviation. Instead, compound 2 reduced 
hTERT-HME1 cell viability in a dose-dependent 
manner. HT-29 viability was reduced by about 70% 
and 50% only at the highest concentration of 
modified NPs of compounds 1 and 2, respectively. 
We treated the hTERT-HME1 and HT-29 cell lines 
also with solutions of fructose, strontium chloride, 
and strontium iodide at the same concentration of 
the modified NPs and that did not alter the cell 
viability (see Figure No.6). We conclude thus that 
the viability is influenced only by the presence of 
the NPs themselves rather than their chemical 
composition, as expected. 
Cell uptake  
The intracellular uptake of modified NPs was 
evaluated by loading fluorescein into the NPs and 
measuring the intracellular fluorescence intensity. 
As shown in Figure No.7, the fluorescence intensity 
was greater when cells were incubated with the 
highest modified NPs concentration, both for 
compounds 1 and 2. Furthermore, it increased as a 
function of the incubation time and it was greater in 
hTERT-HME1 than in HT-29.  
Regarding modified NPs of compound 2, the 
intensity of the intracellular fluorescence increased 
in a dose-dependent manner after 3 h of treatment in 
both cell lines, while there was no dose-dependent 
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Table No.1: Mean diameter± standard error and PDI of the particles obtained by grinding the powders 
on a planetary ball mill, with different revolutions per minute (rpm) and grinding times for compounds 1 
and 2 
S.No Grinding time rpm Mean diameter 
nm ± s.e. (PDI) 
Compound 1 
1 33 min 200 275.4 ± 27.3 (0.305) 
2 44 min 200 236.9 ± 19.6 (0.246) 
3 55 min 200 149.0 ± 11.9 (0.232) 
4 66 min 200 134.9 ± 8.1 (0.227) 
Compound 2 
5 33 min 200 467.2 ± 40.0 (0.005) 
6 44 min 200 432.7 ± 44.0 (0.005) 
7 55 min 200 383.8 ± 74.0 (0.164) 
8 66 min 200 372.5 ± 72.3 (0.320) 
9 74 min 300 333.4 ± 6.0 (0.280) 
10 98 min 300 257.0 ± 3.2 (0.296) 
 
Table No.2: Number density of the radionuclide in the particles ( ) and in tissue ( ) for the 
specified average number of particles per cell. The isotopic dilution factor  and total activity per unit of 
irradiated volume are also reported for a delivered maximum dose . The cell radius is assumed 
to be , as in glioblastoma cell lines 
S.No 
      
1 89Sr(fructose)2I2 1.49×1022 1.08×1016 0.25 1 1.71×109 
2 89Sr(fructose)2Cl2 ·  3H2O 1.38×1022 1.08×1016 0.27 1 1.71×109 
3 Sr(fructose)2131I2 1.13×1022 3.29×1016 1 2.85×10-6 3.28×1010 
 
 
Figure No.1: Crystal structures of compounds 1 (left) and 2 (right). The complete characterization of 
these materials are reported in references 14 and 16 
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Figure No.2: Observation on an optical stereo-microscope of a drop of water with the powder of 
compound 1 reacted with dodecanoyl chloride (left) and with m-PEG (right) 
 
Figure No.3: Chemical surface modification steps aimed to avoid the dissolution of nanoparticles and at 
the same time allow suspension in a biological medium 
 
Figure No.4: XRPD patterns collected for compounds 1 (A) and 2 (B) before treatment (b), after reaction 
with dodecanoyl chloride (c), and after the subsequent covering with mPEG-DSPE (d), compared to the 
respective XRPD patterns calculated from the XRD structures (a) 
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Figure No.5: Antiproliferative activity of nanoparticles of compounds 1 (A) and 2 (B) in hTERT-HME1 
and HT-29 
 
Figure No.6: Antiproliferative activity of solutions of fructose, strontium chloride, and strontium iodide 
in hTERT-HME1 and HT-29 
 
Figure No.7: Cellular uptake of nanoparticles of compounds 1 and 2 in hTERT-HME1 and HT-29 cells 
after 3 and 24 h. Fluorescein was used as a fluorescent dye and the amount of fluorescence intensity in the 
cells was interpreted in terms of cellular internalization capacity. Data are expressed as means ± S.D. of 
at least 3 different experiments, run in triplicate 
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CONCLUSION 
In this work we optimized the synthesis and 
covering of NPs of compounds 1 and 2 in view of 
their use as carriers of 89Sr and 131I into tumor cells. 
The NPs are rapidly and easily synthetized and their 
size can be regulated simply by modulating the 
grinding energy. The chemical modification of the 
NPs surface, in order to allow their dispersion in a 
biological medium, is also simple and fast, this 
being a great advantage for radionuclide therapy 
applications, since both radio-isotopes have a 
relatively short half-life. The modified NPs were 
shown to survive for days in a biological medium 
and internalize into hTERT-HME1 and HT-29 cells. 
The viability of cell lines utilized is influenced by 
the presence of the NPs themselves rather than their 
chemical composition. The NPs formulation could 
be useful to concentrate the effect of 89Sr and 131I in 
a specific tissue, allowing a selective activity of the 
activated compounds. The evaluation of the dose 
absorbed from a tissue exposed to NPs of 
89Sr(fructose)2Cl2 ·  H2O, 89Sr(fructose)2I2, and Sr 
(fructose)2131I2 suggests that these compounds could 
be successfully employed in radionuclide therapy. 
The two β− emitters show complementary features: 
89Sr would ease both the synthesis and the 
functionalization of the particles at the expense of a 
dose somehow limited; 131I, on the other hand, 
would need a fast preparation and use of the 
particles, but it makes a virtually unlimited dose 
readily available. From the above considerations, it 
follows that the calibration of the amount of 89Sr 
and/or 131I inside the NPs, should enable us to 
deliver a specified dose to each patient, thus 
allowing the custom-tailoring of the beta therapy. 
Moreover, we developed a tool to rapidly estimate 
the amount of labeled NPs to be administered to the 
patient, as a function of the required dose to treat a 
tumor mass of a specified size. The great advantage 
of encapsulating the enriched isotopes into NPs are: 
i) the concentration of the enriched isotopes into a 
small volume, that can locally enhance the dose 
administered and reduce side effects to the patient; 
ii) the possibility to easily functionalize the NPs 
surface depending on the target tumor cells. Thus, 
in principle, the same isotope can be used for a wide 
range of tumors by simply varying the 
functionalization of the surface. This will be the aim 
of our further work. 
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